下肢外周动脉疾病患者抗血小板治疗的依从性与持续性:一项丹麦人群队列研究
该研究纳入2010-2017年丹麦≥40岁首次诊断为症状性下肢外周动脉疾病(PAD)且确诊后90天内至少一次申领阿司匹林和/或氯吡格雷处方的患者。23 279例(58.7%)在90天内申领处方,其中12 898例(55.4%)为既往用药者;既往用药者平均PDC为74.5%(SD 35.0%),新用药者为60.5%(SD 30.5%)。结论认为启动率和依从性均不够理想,需改善抗血小板治疗的启动与维持。
要点
- 在新诊断的症状性PAD患者中,不足60%在确诊后90天内申领抗血小板处方。
- 既往用药者1年治疗终止累积发生率为17.2%,新用药者为7.9%。
- 3年累积终止率总体31.5%,既往用药者44.6%,新用药者14.6%。
核心结论
- 不足60%的新诊断症状性PAD患者在确诊后90天内申领抗血小板治疗处方。
- 诊断后第一年内依从性和持续性均为中等水平。
- 作者认为这些发现强调了改善PAD患者抗血小板治疗启动与维持的重要性。
研究设计与样本
- 基于丹麦全国人群的队列研究。
- 纳入2010-2017年间首次住院或门诊诊断为症状性PAD(间歇性跛行和慢性肢体威胁性缺血)、年龄≥40岁、且在诊断后90天内至少一次申领阿司匹林和/或氯吡格雷处方的丹麦公民。
- 共39 687例符合纳入条件,其中23 279例(58.7%)在诊断后90天内申领处方。
- 23 279例中12 898例(55.4%)为既往用药者,其余为新用药者(在PAD诊断后启动治疗)。
- 依从性以诊断后第一年内的覆盖天数比例(PDC)确定;持续性定义为三年随访期间处方续配之间无≥30天的治疗间隙。
主要发现
- 既往用药者平均PDC为74.5%(SD 35.0%),新用药者为60.5%(SD 30.5%)。
- 依从性随年龄和合并用药数量增加而升高。
- 1年治疗终止累积发生率总体为13.0%(95%CI 12.5-13.4%),既往用药者为17.2%(95%CI 16.6-17.9%),新用药者为7.9%(95%CI 7.4-8.4%)。
- 3年随访时治疗终止累积发生率总体为31.5%(95%CI 30.9-32.2%),既往用药者为44.6%(95%CI 43.7-45.4%),新用药者为14.6%(95%CI 13.9-15.3)。
临床怎么用
- 作者认为应努力改善PAD患者抗血小板治疗的启动与维持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Adherence to antiplatelet therapy is recommended but unexplored in patients with symptomatic lower extremity peripheral arterial disease (PAD). Therefore, this study aimed to determine adherence and persistence to antiplatelet therapy in patients with PAD, defined as intermittent claudication and chronic limb threatening ischaemia. DESIGN: Population based nationwide cohort study. METHODS: This study included all Danish citizens aged ≥ 40 years with a first inpatient or outpatient diagnosis of symptomatic PAD between 2010 - 2017, and who had at least one prescription claim for aspirin and/or clopidogrel within 90 days after diagnosis. Adherence was determined by the proportion of days covered (PDC) during the first year after diagnosis. Persistence was defined as no treatment gap ≥ 30 days between prescription renewals over three year follow up. RESULTS: A total of 39 687 patients were eligible for inclusion, of whom 23 279 (58.7%) claimed a prescription for aspirin and/or clopidogrel within 90 days of diagnosis. Among these, 12 898 (55.4%) were prevalent users, while the remainder comprised new users who initiated the therapy after the index PAD diagnosis. The mean PDC was 74.5% (SD 35.0%) for prevalent users and 60.5% (SD 30.5%) for new users. Adherence increased with age and number of concomitant drugs. The overall one year cumulative incidence treatment discontinuation was 13.0% (95% CI 12.5 - 13.4%) overall, 17.2% (CI 16.6 - 17.9%) for prevalent users, and 7.9% (CI 7.4 - 8.4%) for new users. At three year follow up, the cumulative incidence of discontinuation was 31.5% (CI 30.9 - 32.2%) overall, 44.6% (CI 43.7 - 45.4%) for prevalent users, and 14.6% (CI 13.9 - 15.3) for new users. CONCLUSION: Less than 60% of patients with newly diagnosed symptomatic PAD claimed a prescription for antiplatelet therapy within 90 days of diagnosis, and both adherence and persistence were moderate during the first year after diagnosis. These findings underscore the importance of efforts to improve the initiation and continuation of antiplatelet therapy in patients with PAD.
引用
- Thaarup M, Jacobsen S, Nielsen PB, et al. Adherence and Persistence to Antiplatelet Therapy in Lower Extremity Peripheral Arterial Disease: A Danish Population Based Cohort Study. Eur J Vasc Endovasc Surg. 2024. PMID: 38341174. doi:10.1016/j.ejvs.2024.02.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。